GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lerodalcibep   Click here for help

GtoPdb Ligand ID: 14319

Synonyms: LIB-003 | LIB003 | sequence 3 [US10738102B2]
Approved drug
lerodalcibep is an approved drug
Compound class: Peptide
Comment: Lerodalcibep (LIB003) is a small protein that fuses an adnectin (designed to bind proprotein convertase subtilisin/kexin type 9 [PCSK9]) to human serum albumin to achieve an extended circulating half-life and ambient storage stability [3]. It behaves as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [1,4-6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Lerodalcibep was advanced to clinical eval;luations to determine safety and efficacy as a once-monthly injectable tp reduce LDL-C in patients at high risk of atherosclerotic cardiovascular disease (including those with severe inherited high-cholesterol diseases). It was first approved by the US FDA in December 2025, an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04806893 Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction Phase 3 Interventional LIB Therapeutics LLC 2
NCT04034485 Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH Phase 3 Interventional LIB Therapeutics LLC
NCT04797104 Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction Phase 3 Interventional LIB Therapeutics LLC 4